Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of astilbin in preparation of drug for treating diabetic retinopathy

A technology for diabetic retina and astilbin, which is applied to the application field of astilbin in the preparation of a drug for treating diabetic retinopathy, can solve the problems of insignificant treatment effect, unknown side effects, poor compliance and the like, and is suitable for popular use, reducing Aneurysm, the effect of improving compliance

Inactive Publication Date: 2018-03-16
珠海霍普金斯医药研究院股份有限公司 +1
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] At present, in the treatment of diabetic retinopathy, although the toxic and side effects of traditional Chinese medicine are small, the effect is slow and the therapeutic effect is not obvious; the treatment of diabetic retinopathy with western medicine is expensive, with unknown side effects and poor compliance

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of astilbin in preparation of drug for treating diabetic retinopathy
  • Application of astilbin in preparation of drug for treating diabetic retinopathy
  • Application of astilbin in preparation of drug for treating diabetic retinopathy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] Experimental study of astilbin on enhancing endothelium-dependent relaxation in vitro

[0019] SD rats were killed by decapitation, and the thoracic aorta was quickly taken out and immersed in cold Krebs solution. The outer membrane fat and part of the connective tissue were peeled off under the microscope, and the vascular ring of about 5 mm was cut. Put the prepared vascular ring into a petri dish containing 2mL DMEM medium, and divide the vascular ring into the following 5 groups: the blank control group and the valsartan group (10 -7 mol / L) and astilbin high concentration group (10 -5 mol / L), medium concentration group (10 -6 mol / L), low concentration group (10 -7 mol / L), 5 blood vessel loop samples were made for each concentration group, and an equal volume of normal saline was added to the blank control group. Before the experiment, the resting load of the arterial ring was 2mN, and the fluid was changed every 20min, and it was stable for 1.5h. First use 1μmol / L nore...

Embodiment 2

[0025] Astilbin increases retinal thickness in rats with diabetic retinopathy

[0026] After adaptive feeding, SD rats were injected intraperitoneally with 40 mg / kg of streptozotocin (STZ) to prepare a diabetes model. After 72 hours, take blood from the tail of the rat to measure the blood glucose, and the blood glucose concentration is> 16mmol / L is a model rat. Then the rats were randomly divided into 4 groups, namely Xuesaitong group (130mg / kg), astilbin high-dose group (200mg / kg), astilbin low-dose group (50mg / kg), model group, each Group 10 rats. In addition, 6 rats not injected with STZ, but injected with normal saline were used as normal control group.

[0027] The model group and the normal control group were given the same volume of drinking water by gavage for 4 weeks. After 4 weeks, the anesthetized rats were taken from the eyeballs and placed in formalin fixative solution. After dehydration, paraffin embedding and staining with hematoxylin and eosin, the rats' retinal...

Embodiment 3

[0033] Li Moumou, female, 45 years old, had bright red capillary hemangioma in the retina of both eyes at the time of treatment, with flame-like hemorrhage, gray-white exudation and bright red neovascularization in the later stage. 1g of astilbin is taken in 2 doses, 4 weeks as a course of treatment. Symptoms such as bleeding spots, inflammatory exudation, and intraretinal microvascular abnormalities (IRMA) were significantly improved after taking the medicine for one month. At the same time, no other abnormal clinical symptoms were found compared with the previous treatment. He continued to take the medicine for another 3 months and healed. There was no recurrence after 1 year of follow-up.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to new application of astilbin, in particular to application of astilbin in preparation of a drug for treating diabetic retinopathy. The astilbin can improve the symptoms of thediabetic retinopathy, including remarkable decrease of arterial aneurysms, bleeding flecks, inflammatory exudation, cotton-wool spots, venous beading, intraretinal microvascular abnormalities (IRMAS),macular oedema and other symptoms. Any clinic toxic or side effect of the astilbin is not found, and raw materials are non-toxic, so that the treatment compliance can be improved. The raw materials are easy to obtain, and the astilbin is suitable for popular use and has a very good application prospect.

Description

Technical field [0001] The invention relates to a new use of astilbin, in particular to the application of astilbin in the preparation of drugs for treating diabetic retinopathy. Background technique [0002] Diabetic retinopathy (DR) is the most important manifestation of diabetic microangiopathy, a fundus disease with specific changes, and one of the serious complications of diabetes. Clinically, based on whether there is retinal neovascularization as a marker, diabetic retinopathy without retinal neovascularization is called non-proliferative diabetic retinopathy (NPDR) (or simple or background type), and there will be retinal neovascularization. The resulting diabetic retinopathy is called proliferative diabetic retinopathy (PDR). The lesions of retinal capillaries include aneurysms, bleeding spots, hard exudates, cotton wool spots, beaded veins, intraretinal microvascular abnormalities (IRMA), and macular edema. Extensive ischemia can cause retinal or optic disc neovascula...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7048A61P3/10A61P9/10A61P27/02
CPCA61K31/7048
Inventor 曹文强赵柏松
Owner 珠海霍普金斯医药研究院股份有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com